Cargando…

Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease

Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Amy, Sánchez, Saray, Berti, Giulio, Pan-Castillo, Belen, Nijhuis, Anke, Mehta, Shameer, Eleid, Liliane, Gordon, Hannah, Gadhok, Radha, Kimberley, Christopher, Minicozzi, Annamaria, Chin-Aleong, Joanne, Feakins, Roger, Kypta, Robert, Lindsay, James Oliver, Silver, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583737/
https://www.ncbi.nlm.nih.gov/pubmed/36156078
http://dx.doi.org/10.1042/CS20210889
_version_ 1784813133709180928
author Lewis, Amy
Sánchez, Saray
Berti, Giulio
Pan-Castillo, Belen
Nijhuis, Anke
Mehta, Shameer
Eleid, Liliane
Gordon, Hannah
Gadhok, Radha
Kimberley, Christopher
Minicozzi, Annamaria
Chin-Aleong, Joanne
Feakins, Roger
Kypta, Robert
Lindsay, James Oliver
Silver, Andrew
author_facet Lewis, Amy
Sánchez, Saray
Berti, Giulio
Pan-Castillo, Belen
Nijhuis, Anke
Mehta, Shameer
Eleid, Liliane
Gordon, Hannah
Gadhok, Radha
Kimberley, Christopher
Minicozzi, Annamaria
Chin-Aleong, Joanne
Feakins, Roger
Kypta, Robert
Lindsay, James Oliver
Silver, Andrew
author_sort Lewis, Amy
collection PubMed
description Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and transforming growth factor β1 (TGFβ) signalling pathways, and assesses the therapeutic potential of small-molecule Wnt inhibitors. β-catenin expression was explored by immunohistochemistry (IHC) in formalin-fixed paraffin embedded (FFPE) tissue from patient-matched nonstrictured (NSCD) and strictured (SCD) intestine (n=6 pairs). Functional interactions between Wnt activation, TGFβ signalling, and type I collagen (Collagen-I) expression were explored in CCD-18Co cells and primary CD myofibroblast cultures established from surgical resection specimens (n=16) using small-molecule Wnt inhibitors and molecular techniques, including siRNA-mediated gene knockdown, immunofluorescence (IF), Wnt gene expression arrays, and western blotting. Fibrotic SCD tissue was marked by an increase in β-catenin-positive cells. In vitro, activation of Wnt-β-catenin signalling increased Collagen-I expression in CCD-18Co cells. Conversely, ICG-001, an inhibitor of β-catenin signalling, reduced Collagen-I expression in cell lines and primary CD myofibroblasts. TGFβ increased β-catenin protein levels but did not activate canonical Wnt signalling. Rather, TGFβ up-regulated WNT5B, a noncanonical Wnt ligand, and the Wnt receptor FZD8, which contributed directly to the up-regulation of Collagen-I through a β-catenin-independent mechanism. Treatment of CCD-18Co fibroblasts and patient-derived myofibroblasts with the FZD8 inhibitor 3235-0367 reduced extracellular matrix (ECM) expression. Our data highlight small-molecule Wnt inhibitors of both canonical and noncanonical Wnt signalling, as potential antifibrotic drugs to treat SCD intestinal fibrosis. They also highlight the importance of the cross-talk between Wnt and TGFβ signalling pathways in CD intestinal fibrosis.
format Online
Article
Text
id pubmed-9583737
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-95837372022-10-27 Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease Lewis, Amy Sánchez, Saray Berti, Giulio Pan-Castillo, Belen Nijhuis, Anke Mehta, Shameer Eleid, Liliane Gordon, Hannah Gadhok, Radha Kimberley, Christopher Minicozzi, Annamaria Chin-Aleong, Joanne Feakins, Roger Kypta, Robert Lindsay, James Oliver Silver, Andrew Clin Sci (Lond) Pharmacology & Toxicology Intestinal fibrosis and stricture formation is an aggressive complication of Crohns disease (CD), linked to increased morbidity and costs. The present study investigates the contribution of Wingless-Int-1 (Wnt) signalling to intestinal fibrogenesis, considers potential cross-talk between Wnt and transforming growth factor β1 (TGFβ) signalling pathways, and assesses the therapeutic potential of small-molecule Wnt inhibitors. β-catenin expression was explored by immunohistochemistry (IHC) in formalin-fixed paraffin embedded (FFPE) tissue from patient-matched nonstrictured (NSCD) and strictured (SCD) intestine (n=6 pairs). Functional interactions between Wnt activation, TGFβ signalling, and type I collagen (Collagen-I) expression were explored in CCD-18Co cells and primary CD myofibroblast cultures established from surgical resection specimens (n=16) using small-molecule Wnt inhibitors and molecular techniques, including siRNA-mediated gene knockdown, immunofluorescence (IF), Wnt gene expression arrays, and western blotting. Fibrotic SCD tissue was marked by an increase in β-catenin-positive cells. In vitro, activation of Wnt-β-catenin signalling increased Collagen-I expression in CCD-18Co cells. Conversely, ICG-001, an inhibitor of β-catenin signalling, reduced Collagen-I expression in cell lines and primary CD myofibroblasts. TGFβ increased β-catenin protein levels but did not activate canonical Wnt signalling. Rather, TGFβ up-regulated WNT5B, a noncanonical Wnt ligand, and the Wnt receptor FZD8, which contributed directly to the up-regulation of Collagen-I through a β-catenin-independent mechanism. Treatment of CCD-18Co fibroblasts and patient-derived myofibroblasts with the FZD8 inhibitor 3235-0367 reduced extracellular matrix (ECM) expression. Our data highlight small-molecule Wnt inhibitors of both canonical and noncanonical Wnt signalling, as potential antifibrotic drugs to treat SCD intestinal fibrosis. They also highlight the importance of the cross-talk between Wnt and TGFβ signalling pathways in CD intestinal fibrosis. Portland Press Ltd. 2022-10 2022-10-14 /pmc/articles/PMC9583737/ /pubmed/36156078 http://dx.doi.org/10.1042/CS20210889 Text en © 2022 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pharmacology & Toxicology
Lewis, Amy
Sánchez, Saray
Berti, Giulio
Pan-Castillo, Belen
Nijhuis, Anke
Mehta, Shameer
Eleid, Liliane
Gordon, Hannah
Gadhok, Radha
Kimberley, Christopher
Minicozzi, Annamaria
Chin-Aleong, Joanne
Feakins, Roger
Kypta, Robert
Lindsay, James Oliver
Silver, Andrew
Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title_full Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title_fullStr Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title_full_unstemmed Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title_short Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
title_sort small-molecule wnt inhibitors are a potential novel therapy for intestinal fibrosis in crohns disease
topic Pharmacology & Toxicology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583737/
https://www.ncbi.nlm.nih.gov/pubmed/36156078
http://dx.doi.org/10.1042/CS20210889
work_keys_str_mv AT lewisamy smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT sanchezsaray smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT bertigiulio smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT pancastillobelen smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT nijhuisanke smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT mehtashameer smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT eleidliliane smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT gordonhannah smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT gadhokradha smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT kimberleychristopher smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT minicozziannamaria smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT chinaleongjoanne smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT feakinsroger smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT kyptarobert smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT lindsayjamesoliver smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease
AT silverandrew smallmoleculewntinhibitorsareapotentialnoveltherapyforintestinalfibrosisincrohnsdisease